@therestoreclinic's TRT video claims need more context

What did @therestoreclinic actually say?

The creator's position is that adding HCG to a TRT protocol does not raise testosterone levels enough to justify lowering your testosterone dose. They laid out three reasons: HCG-only patients often still have low testosterone, long-term HCG use can cause Leydig cell desensitization, and HCG still suppresses LH from the pituitary. They also pushed back on the idea that HCG is a universal fix in TRT, calling it something with real pros and cons.

This is a more nuanced take than what circulates on TRT forums, where HCG gets treated as a near-magical add-on. The creator is specifically addressing a patient question about dose reduction, not HCG's other roles like preserving testicular function or fertility. That framing matters when evaluating whether the claims hold up.

Does the science back this up?

Mostly, yes. The evidence supports all three of the creator's core claims, though the picture is more complicated than the video suggests.

On Leydig cell desensitization: this is a real and documented phenomenon. Sriraman et al. (2003, Molecular Endocrinology) demonstrated that chronic LH or HCG stimulation downregulates LH receptor expression in Leydig cells, reducing steroidogenic response over time. This isn't fringe science. It's been observed in both animal models and human clinical settings.

On LH suppression: HCG is an LH analog. When you inject it, the pituitary reads a signal that says gonadotropin activity is already happening and reduces endogenous LH output. Depenbusch et al. (2002, European Journal of Endocrinology) showed that HCG administration suppresses endogenous LH secretion in hypogonadal men, consistent with what the creator described.

On HCG-only protocols producing modest testosterone: this tracks with clinical experience and available data. Coviello et al. (2004, Journal of Clinical Endocrinology and Metabolism) found that HCG can stimulate testosterone production, but responses vary widely and do not reliably push testosterone into the therapeutic range for all men, particularly those with primary or longstanding hypogonadism.

What did they get wrong (or right)?

The creator gets the broad strokes right, but a few things deserve scrutiny.

The claim that HCG does not raise testosterone enough to warrant dose reduction is generally accurate for the population they describe, men already on exogenous testosterone. But it is not universally true. In men with secondary hypogonadism and intact Leydig cell function, HCG can produce a meaningful testosterone increase. Ramasamy et al. (2014, Journal of Urology) found that HCG monotherapy restored testosterone to normal levels in a subset of hypogonadal men. The creator's clinical observation may reflect selection bias toward patients who have already been on testosterone long enough to have Leydig cell atrophy.

The framing around "1000 IU's two, three times a week" is worth flagging. That is a high-dose HCG protocol. Most contemporary clinical guidelines and fertility literature use substantially lower doses when HCG is added adjunctively to TRT. Presenting very high-dose failures as evidence against HCG dose adjustment in general is not a clean argument.

That said, the LH suppression point is accurate and underappreciated. Many patients and even some practitioners treat HCG as if it preserves the HPG axis completely. It does not.

What should you actually know?

HCG serves different purposes in different clinical contexts, and conflating them creates confusion.

When added to TRT, HCG is typically used to maintain intratesticular testosterone, preserve Leydig cell function, and support fertility, not to meaningfully replace or reduce exogenous testosterone. Liu et al. (2009, Journal of Clinical Endocrinology and Metabolism) showed that low-dose HCG added to testosterone maintained intratesticular testosterone and sperm production, but the systemic serum testosterone increase from HCG alone in this context was modest.

The desensitization concern is real but not inevitable or irreversible. It is dose and duration dependent. Rotating protocols or using lower doses may mitigate this, though that is a clinical conversation, not something to self-manage.

• HCG does not replace TRT for most men already on testosterone therapy.
• Long-term or high-dose HCG use can reduce Leydig cell responsiveness over time.
• HCG suppresses endogenous LH because it acts as an LH analog, not a supplement to the HPG axis.
• Response to HCG varies significantly based on the underlying cause of hypogonadism and how long someone has been on testosterone.
• Dose decisions should be based on lab values and symptoms, not assumptions about what HCG is contributing.